 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

China Universal Asset Management Co. Ltd. bought a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to its most recent 13F filing with the...

China Universal Asset Management Co. Ltd. Invests $105,000 in Autolus Therapeutics plc (NASDAQ:AUTL)

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) dropped 7.5% during trading on Monday . The stock traded as low as $5.90 and last traded at $5.90. Approximately 1,050,329 shares were traded...

Autolus Therapeutics (NASDAQ:AUTL)  Shares Down 7.5%

Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing application is under review with a Prescription Drug User Fee Act (PDUFA) target action...

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL

This price move could indicate a change in the trend, and may be a sell signal for investors...

Autolus Therapeutics (AUTL, $5.68) price exceeded its 50-day Moving Average on April 01, 2024

This indicator may be signaling that AUTL's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Autolus Therapeutics plc (AUTL, $5.68) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

The latest announcement is out from Autolus Therapeutics Plc (AUTL). John Johnson has stepped down from his role as the chair of Autolus Therapeuti...

Autolus Therapeutics Announces Board Leadership Changes

LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today...

Autolus Therapeutics Announces Changes to its Board of Directors

B. Riley Wealth Advisors Inc. decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL  Free Report) by 22.7% in the 3rd quarter, according to the company in its most recent filing with...

Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by B. Riley Wealth Advisors Inc.

Autolus Therapeutics plc (NASDAQ:AUTL  Get Free Report) shares gapped up before the market opened on Monday . The stock had previously closed at $6.32, but opened at $6.48. Autolus...

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $6.32

Autolus Therapeutics plc (NASDAQ:AUTL  Get Free Report)s stock price fell 4.6% during trading on Thursday . The stock traded as low as $6.23 and last traded at $6.25. 240,860 shares...

Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 4.6%

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Volume (M)	2,057.00
52-Wk High	$7.45
52-Wk Low	$1.61

AUTL Autolus Therapeutics Ltd - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals